A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice yearly investigational pre-exposure prophylaxis (PrEP) injection.
WHO logo © dennizn - stock.adobe.com
The World Health Organization (WHO) has announced the upcoming development of new lenacapavir and HIV testing guidelines, according to a news release published Monday. Guidelines will be determined during the Guideline Development Group (GDG) meeting, which will be held virtually from Jan. 28-30, 2025. Interested members of the public can submit questions and provide feedback by emailing hiv-aids@who.int until Jan. 20, 2024.
The meeting will establish the framework for implementing lenacapavir as a pre-exposure prophylaxis (PrEP) regimen and simplify current and long-term options for HIV testing models. Members will also discuss the safety and efficacy of lenacapavir, with extra focus paid to initiation in low-resource areas.
Lenacapavir targets the HIV capsid, the genetic shell that protects the virus’s genetic material, preventing replication. It is currently approved in the United States to treat patients with multi-drug-resistant HIV in combination with other antiretrovirals, but not as a form of PrEP.
Drugmaker Gilead submitted a new drug application for FDA approval for lenacapavir as a form of PrEP on Dec. 19, 2024. The submission was supported using data from the Purpose 1 trial, which demonstrated that lenacapavir had 100% efficacy in preventing HIV in cisgender women in Uganda and South Africa, when compared with patients treated with once-daily oral Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg). In the Purpose 2 trial, there was a 99.9% efficacy rate and a 96% reduction in HIV cases, a Gilead news release states.
The FDA also granted lenacapavir a rolling review and breakthrough therapy designation in October 2024. Science Magazine also named it “Breakthrough Drug of the Year.”
As an injectable form of PrEP, lenacapavir has the potential to change the HIV landscape, though its high cost remains a barrier – up to $44,819 per person annually in the United States, despite an estimated mass production cost of less than $100 per person annually, a cost analysis published in the Journal of Antimicrobial Chemotherapy reports. In October 2024, Gilead signed royalty-free voluntary licensing agreements with six generic manufacturers to produce the drug in 120 high-incidence, primarily low-income countries. These include 18 countries that account for 70% of global HIV cases.
Members of the GDG come from all WHO regions and are chosen based on their levels of expertise and commitment to educate about and end the HIV epidemic.
There is currently no cure for HIV or AIDS.
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More
Most HIV Patients Trust Their Providers But Don’t Always Feel Heard, Survey Says
May 27th 2025Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.
Read More
HIV Antiretroviral Reduced Alzheimer’s Risk Continuously, Study Shows
May 8th 2025Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.
Read More